Adverse events (⩾ 10%)
| Adverse events | Period II | Period III | |||
|---|---|---|---|---|---|
| Clozapine (N = 32) | Placebo (N = 28) | Clozapine (N = 30) | Formerly placebo* (N = 25) | All (N = 55) | |
| *Patients receiving placebo during period II. | |||||
| Worsening of Parkinson’s disease | 7 (21.8%) | 1 (4%) | 4 (13%) | 3 (12%) | 7 (13%) |
| Sialorrhoea | 3 (9%) | 0 | 0 | 5 (20%) | 5 (9%) |
| Confusion | 0 | 2 (7%) | 1 | 3 (12%) | 4 (7%) |
| Somnolence | 17 (53%) | 5 (18%) | 3 (10%) | 11 (44%) | 14 (25%) |
| Nausea/vomiting | 0 | 4 (15%) | 2 (7%) | 3 (12%) | 5 (9%) |
| Constipation | 1 (3%) | 1 (4%) | 2 (7%) | 3 (12%) | 5 (9%) |
| Postural hypotension | 6 (19%) | 4 (14%) | 1 (3%) | 4 (16%) | 5 (9%) |
| Respiratory infection | 5 (16%) | 3 (11%) | 6 (20%) | 4 (16%) | 10 (18%) |
| General condition aggravated | 0 | 3 (11%) | 0 | 2 (8%) | 2 (4%) |
| Syncope/malaise | 0 | 4 (15%) | 0 | 1 (4%) | 1 (2%) |